Pinpoint the
right targets

Target identification and deconvolution focus on understanding which biological targets drive the observed effect and whether they are suitable for further investment. Work typically starts with hypotheses based on genetics, pathway analysis, phenotypic observations, or published data. Experimental systems are selected to reflect the disease context, and studies are designed to test whether modulating the proposed target or pathway leads to the expected biological response.

In phenotypic discovery programs where the mechanism is unclear, deconvolution studies are used to identify the most likely molecular target and related proteins that influence the phenotype. Study design emphasizes separating direct target effects from downstream pathway responses or assay artifacts. Appropriate controls and complementary experiments are employed to confirm that observed effects are robust and biologically meaningful before proceeding.

Uncover your targets with Proteome Wide Profiling

In this phase, CETSA can support target identification and deconvolution by providing direct evidence of cellular target engagement in disease-relevant models. By anchoring phenotypic or hypothesis-driven findings to specific protein interactions, CETSA helps clarify which targets are most likely responsible for the observed effect and which signals reflect indirect or downstream biology.

Target identification and deconvolution is enabled by our Proteome Wide Profiling Service

Proteome Wide Profiling

Broader investigation of compound effects across the detectable proteome.

Learn more

The power of Proteome-wide CETSA

Explore case studies on cancer therapies, antimalarial drug targets, and fungal-derived small molecules, showcasing CETSA’s ability to uncover novel targets.

Learn more

Are you using the right tools?

Early integration of CETSA technology can help you streamline your discovery pipeline, minimize late-stage failures, and uncover novel targets faster than traditional methods.

Learn more